FibroGen limits rare-disease drug's access after clinical trial failure. Some parents say it was saving their kids' lives
'How long before my heart fails?' Tanner Edwards asked his mom after losing access to a FibroGen drug he's taken for six years for Duchenne muscular dystrophy.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Cardiology | Children | Clinical Trials | Health Management | Heart | Muscular Dystrophy | Pharmaceuticals | Rare Diseases | Reflex Sympathetic Dystrophy